Current Cancer Vaccine and Immunotherapy Trials
Current Trials: Breast Cancer
A Phase II Trial of the Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes from Five Antigens Associated with Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Patients with Triple Negative Breast Cancer
Study Stage
Phase II
Stage of Disease
I, II or III
Tumor Type
Triple Negative Breast Cancer (TNBC)
Study Treatment
Vaccine
Study Population
A Phase II Trial of the Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes from Five Antigens Associated with Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Patients with Triple Negative Breast Cancer+C17
Results Summary
A Phase II Study of Concurrent WOKVAC Vaccination with Neoadjuvant Chemotherapy and HER2-Targeted Monoclonal Antibody Therapy
Study Stage
Phase II
Stage of Disease
I, II, III
Tumor Type
Breast
Study Treatment
Vaccine + chemo+HER2-targeted monoclonal antibody
Study Population
Patients with HER2+ breast cancer, regardless of hormone receptor status, who are planning to receive neoadjuvant cytotoxic chemotherapy and HER2-targeted monoclonal antibody therapy prior to planned surgery.
Results Summary
A Phase I Dose Escalation Trial of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients with Treatment Refractory HER2+ Metastatic Breast Cancer
Study Stage
Phase I
Stage of Disease
IV
Tumor Type
Breast
Study Treatment
Vitamin E derivative + HER2 targeted monoclonal antibody
Study Population
Stage IV HER2+ breast cancer who have been treated with definitive therapy and received maintenance HER2-targeted monoclonal antibody therapy; and currently have measurable disease not considered curable by conventional therapies.
Results Summary
Current Trials: Ovarian Cancer
A Phase II Study of Anti-PD-1 in Combination with Carboplatin to Prevent Progression after Serologic Detection of Recurrent Ovarian Cancer
Study Stage
Phase II
Stage of Disease
III, IV
Tumor Type
Ovarian, fallopian tube, peritoneal
Study Treatment
Chemo + Anti-PD-1 therapy
Study Population
Ovarian, fallopian tube, primary peritoneal cancer in complete remission undergoing cancer surveillance found to have CA-125 elevation, but no radiographic evidence of recurrence.
Results Summary
Current Trials: Non-Small Cell Lung Cancer
A Phase II Randomized Study of Safety and Efficacy of a Multiple Antigen Vaccine (STEMVAC) in Non-Small-Cell Lung Cancer (NSCLC) Patients
Study Stage
Phase II
Stage of Disease
IV
Tumor Type
Non-small cell lung cancer (NSCLC)
Study Treatment
Vaccine
Study Population
Patients with histologically-confirmed diagnosis of stage IV NSCLC, who are not eligible for approved targeted therapies, have completed 3 - 4 cycles of chemoimmunotherapy (induction treatment), have achieved responsive or stable measurable disease and are receiving or are candidates to continue maintenance treatment with pembrolizumab +/- pemetrexed
Results Summary
Current Trials: Other/Multiple Cancers
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)
Study Stage
Phase II
Stage of Disease
IV
Tumor Type
bladder, biliary tract, cervical, endometrial, ovarian, pancreatic, other rare tumors
Study Treatment
Trastuzumab Deruxtecan (T-DXd)
Study Population
Patients with stage IV HER2 expressing disease who have progressed following at least one prior systemic treatment for metastatic or advanced disease. A total of 15 eligible patients will be enrolled
Results Summary
Past Cancer Vaccine and Immunotherapy Trials
Do you think you might be eligible for one of our cancer vaccine trials?
For more information regarding CVI cancer vaccine and immunotherapy trials, please call our Patient Coordinator at 866-932-8588, or send an email to cvitrial@uw.edu. We strive to get in touch within 48 hours of receiving your inquiry.
Clinicians interested in receiving regular updates on open clinical trials may send a request to be added to our mailing list to kkd@uw.edu.
WHAT'S NEW AT THE CVI
